Healthcare of Ontario Pension Plan Trust Fund Sells 41,073 Shares of Thermo Fisher Scientific Inc. $TMO

Posted by George Bondi on Jul 26th, 2026

Healthcare of Ontario Pension Plan Trust Fund reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 81,049 shares of the medical research company’s stock after selling 41,073 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Thermo Fisher Scientific were worth $39,838,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. J. Stern & Co. LLP raised its holdings in Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $3,072,744,000. Auto Owners Insurance Co increased its position in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after buying an additional 2,423,706 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in Thermo Fisher Scientific by 2,183.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after buying an additional 1,270,643 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Thermo Fisher Scientific by 19.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock worth $4,462,550,000 after buying an additional 1,230,872 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research analyst reports. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley reissued an “overweight” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday. Finally, Jefferies Financial Group restated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $613.05.

Read Our Latest Research Report on TMO

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $567.34 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $210.83 billion, a P/E ratio of 30.52, a PEG ratio of 2.49 and a beta of 0.87. The stock’s 50 day moving average is $494.01 and its 200 day moving average is $513.46.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.